ARA-290
A non-hematopoietic erythropoietin fragment engineered to trigger tissue repair and quiet inflammation without raising red blood cells.
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B surface of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR) — an EPO-receptor/beta-common-receptor (CD131) heterocomplex — to deliver EPO's anti-inflammatory, anti-apoptotic, and neuroprotective effects while avoiding the erythrocytosis, hypertension, and thrombotic risk of full EPO. Multiple published Phase 2 trials support its use in small fiber neuropathy (particularly sarcoidosis-associated) and diabetic neuropathy, though it remains an investigational, non-FDA-approved compound.
Class
Synthetic 11-amino-acid non-hematopoietic erythropoietin (EPO) analogue
Half-life
Short plasma half-life (minutes to tens of minutes); one source cites ~3 hours. Biological effects persist hours to days after clearance.
Routes
Subcutaneous (evidence-based), Intravenous (not clinically studied)
Category
Healing & Recovery
Researched benefits
What it's studied for
Neuropathic pain relief in small fiber neuropathy
The strongest evidence base — multiple published Phase 2 trials in sarcoidosis-associated small fiber neuropathy show reduced pain scores, improved neuropathy-specific symptom scales (SFNSL), autonomic symptom improvement, and better quality of life over 28 days to several months of daily 4 mg dosing.
Small nerve fiber regeneration
Clinical trials have documented increased corneal nerve fiber area and intraepidermal nerve fiber density (IENFD) on skin biopsy with treatment, indicating measurable anatomic nerve regrowth rather than only symptomatic relief.
Anti-inflammatory signaling
IRR activation lowers TNF-alpha, IL-6, IL-1beta, and IL-8, raises anti-inflammatory IL-10, and shifts macrophages toward a resolving M2 phenotype — a tissue-protective signature achieved through a receptor pathway distinct from EPO's hematopoietic effects.
Metabolic and diabetic neuropathy improvement
A Phase 2 RCT in type 2 diabetes showed ARA-290 improved HbA1c, lipid profiles, PainDetect neuropathy scores, and corneal nerve fiber density over 28 days, consistent with improved microvascular perfusion and nerve protection.
Tissue repair without erythropoiesis
By selectively engaging the innate repair receptor and not the classical EPO homodimer, ARA-290 delivers pro-regenerative and anti-apoptotic effects (via JAK2/STAT3, MAPK, and PI3K/Akt) without raising hematocrit, blood pressure, or thrombotic risk.
Mechanism
How it works
Erythropoietin has two distinct receptor targets. The classical EPO receptor (EPOR/EPOR homodimer) on bone marrow erythroid progenitors drives red blood cell production via JAK2/STAT5 and has high affinity for EPO. EPO also binds a lower-affinity heteromeric complex — the innate repair receptor (IRR), made of EPOR plus the beta-common receptor (CD131) — which is expressed on neurons, Schwann cells, cardiomyocytes, vascular endothelium, retinal cells, renal tubular cells, skin fibroblasts, and immune cells, and drives tissue protection and anti-inflammatory signaling.
The engineering problem with using recombinant EPO for tissue protection is that the doses needed to activate the low-affinity IRR also robustly activate the hematopoietic homodimer, producing polycythemia, hypertension, and thrombotic risk. ARA-290's sequence (QEQLERALNSS) corresponds to the external surface of helix B of EPO — a region predicted by crystal-structure analysis to contact the beta-common receptor of the IRR but not the classical EPO-receptor binding interface. The peptide therefore stabilizes and activates the IRR without meaningfully engaging the erythropoietic receptor.
Downstream, IRR activation triggers JAK2/STAT3 signaling (anti-apoptotic BCL-2/BCL-xL upregulation, IL-10 and SOCS3 induction), MAPK/ERK/p38 signaling (proliferation, regeneration, inflammatory resolution), and PI3K/Akt signaling (cell survival and metabolic regulation), while modulating NF-kB to reduce pro-inflammatory cytokines. In nerve tissue this supports neuronal survival, Schwann cell function, axonal regeneration, and increased intraepidermal nerve fiber density, alongside improved endothelial nitric oxide activity and microvascular perfusion.
Pharmacokinetically, ARA-290 has a short plasma half-life typical of small peptides, but its biological effects are durable — lasting hours to days — because the downstream gene-expression and tissue-signaling cascade outlasts the peptide's presence. Clinical trials have confirmed the selectivity goal: at therapeutic doses ARA-290 does not raise hematocrit, blood pressure, or thrombotic risk.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Most common preparation: reconstitute a 16 mg vial with 4 mL bacteriostatic water for a 4 mg/mL concentration, where a 4 mg dose = 1 mL = 100 units on an insulin syringe (2 mg = 0.5 mL = 50 units; 1 mg = 0.25 mL = 25 units). Alternatives: 8 mL water yields 2 mg/mL (smaller doses, larger volume for 4 mg) or 2 mL water yields 8 mg/mL (double-strength, smaller injection volume). Add water slowly down the vial wall, do not shake — gently swirl. The clear, colorless solution stores refrigerated at 2-8C for 28-30 days; lyophilized powder is stable 2+ years refrigerated and protected from light.
Beginner
- Dose
- 2 mg week 1, then 4 mg
- Frequency
- Once daily
- Timing
- Morning or evening; not meal-dependent (SubQ)
- Duration
- 4-6 week initial trial, evaluate response at week 4
- Route
- Subcutaneous
Conservative titration at half the trial dose for the first week to assess injection-site tolerance, then step to the standard 4 mg. For a specific indication only (e.g. small fiber neuropathy, diabetic neuropathy), not general wellness.
Intermediate / Standard
- Dose
- 4 mg
- Frequency
- Once daily (continuous)
- Timing
- Consistent time each day; rotate injection sites daily
- Duration
- 3-6 months or longer based on response
- Route
- Subcutaneous
The clinical-trial-established dose for sarcoidosis-SFN and diabetic neuropathy. Higher doses have not shown superior efficacy in trials, consistent with receptor saturation at lower doses. Focus is on sustained use, stacking, and outcome tracking rather than dose escalation.
Advanced / Refractory
- Dose
- 4 mg (no dose increase)
- Frequency
- Once daily, continuous
- Timing
- Consistent daily; rigorous site rotation
- Duration
- 6-12+ months with enhanced monitoring
- Route
- Subcutaneous
'Advanced' does NOT mean higher doses — evidence does not support exceeding 4 mg/day or non-SubQ routes. It means longer courses, comprehensive stacking for complex cases, and rigorous outcome measurement (IENFD skin biopsy, autonomic testing, QST). Clinical trial enrollment is often the best route.
Maintenance / Cost-managed (community, limited evidence)
- Dose
- 4 mg every other day or 2 mg daily
- Frequency
- Alternate-day or daily
- Timing
- Consistent schedule
- Duration
- After 8-12 weeks of response at 4 mg daily
- Route
- Subcutaneous
Anecdotal community schedules to reduce cost after initial response. Pulsing (3 months on, 1 month off) is also used. Trial protocols were daily; these modified schedules are not trial-validated.
- Subcutaneous injection is the only route with clinical evidence; intranasal, IV, oral, and topical routes have no human efficacy data (oral peptide is degraded in the GI tract).
- Effects are gradual, not acute — do not expect to 'feel' anything in the first week or two. Significant improvement over placebo typically emerged at week 2-4, with peak response around 6-12 weeks.
- Give at least 4-6 weeks at 4 mg daily before judging response; some users do not see peak benefit until 2-3 months, and non-responders rarely convert with higher doses or longer time.
- Rotate injection sites daily (abdomen, thigh, upper arm SubQ) to avoid localized reactions, scarring, and lipodystrophy with long-term use.
- ARA-290 is among the most expensive peptide interventions — roughly $150-300+ per 16 mg vial (about 4 days at 4 mg daily), translating to roughly $1,200-2,400+ per month at the full dose.
- Baseline and periodic monitoring: CBC (confirm stable hematocrit), CMP, and blood pressure every 4-8 weeks, plus condition-specific symptom scales and biomarkers; consider IENFD skin biopsy and autonomic testing for objective nerve outcomes.
Evidence
Research & clinical studies (3)
ARA 290, a non-hematopoietic erythropoietin analogue, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Over 28 days, ARA-290 improved HbA1c, lipid profiles, PainDetect neuropathy scores, and corneal nerve fiber density in type 2 diabetes patients, consistent with tissue-protective IRR signaling independent of erythropoiesis.
PMID 25387363Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients
In a Phase 2b randomized trial of 64 sarcoidosis patients with small nerve fiber loss, cibinetide 4 mg significantly increased corneal nerve fiber area (p=0.012), and improvements correlated with functional gains on the 6-minute walk test.
PMID 28475703Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice
ARA-290 improved insulin sensitivity and altered immune cell profiles in diabetic mice but did not restore impaired executive cognitive flexibility, indicating peripheral metabolic improvement alone is insufficient to rescue inflammation-linked executive deficits.
PMID 41933665Combinations
Stacking & blends
Enhanced Neuropathic Pain Protocol
Maximize nerve protection and regeneration in painful peripheral neuropathy
Layers ARA-290's IRR-mediated anti-inflammatory and nerve-regenerative effects with established neuropathy support nutrients that act on mitochondrial and metabolic nerve pathways, alongside standard neuropathic pain medications.
Comprehensive Recovery / Post-Surgical Stack
Multi-pathway soft-tissue and injury recovery
Each peptide targets a different arm of repair — ARA-290 for inflammation reduction and cellular protection, BPC-157 for epithelial/angiogenic effects, TB-500 for cell migration and matrix remodeling — making the mechanisms theoretically additive.
Sarcoidosis Comprehensive Adjunct
Adjunctive anti-inflammatory support for sarcoidosis-associated small fiber neuropathy
ARA-290 provides IRR-mediated tissue protection while KPV adds NF-kB-directed anti-inflammatory activity; used alongside standard sarcoidosis therapy (steroids, methotrexate, anti-TNF) with vitamin D monitoring. Coordinate with a specialist.
Multi-System Inflammatory / Autoimmune Adjunct
Broad immune modulation and inflammation resolution
Combines ARA-290's innate repair signaling with KPV's anti-inflammatory action and Thymosin Alpha-1's immune modulation; monitor for infection risk when layering anti-inflammatory agents.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active erythrocytosis / polycythemia (coordinate with hematology)
- Known hypersensitivity to ARA-290 or bacteriostatic water excipients
- Active malignancy or recent (<5 year) cancer history without oncology clearance
- Untreated serious active infection or sepsis
- Pregnancy and lactation (no human safety data)
- Active or recent (<6 months) thrombotic event, use with caution and physician oversight
- Recent surgery (allow healing; stop 7-14 days before elective surgery)
ARA-290's safety profile in Phase 2 trials has been notably clean — no thrombotic events, no hypertension, and no increase in hematocrit at therapeutic doses, validating its receptor-selective design. Short-term safety up to ~6 months is well tolerated; long-term data beyond 6-12 months are limited. Theoretical concerns include effects on immune surveillance and anti-apoptotic signaling in tumor cells, so active or recent cancer requires oncology coordination. It is compatible with corticosteroids, common immunomodulators, diabetes medications, and other research peptides, with no meaningful effect on coagulation.
FAQ
ARA-290 — common questions
What makes ARA-290 different from EPO?
ARA-290 is an 11-amino-acid fragment of EPO's helix B surface engineered to selectively activate the innate repair receptor (tissue protection, anti-inflammatory) without engaging the classical EPO receptor that drives red blood cell production. In trials it does NOT increase hematocrit, raise blood pressure, or cause thrombosis — so it delivers EPO's protective biology without EPO's cardiovascular risks.
Does ARA-290 actually work for small fiber neuropathy?
Based on multiple published Phase 2 trials, yes — particularly for sarcoidosis-associated small fiber neuropathy, where 4 mg daily for 28 days improved pain scores, symptom scales, autonomic symptoms, quality of life, and objective nerve fiber measures. Diabetic neuropathy evidence is positive but more preliminary. It is still investigational, not FDA-approved.
How quickly does ARA-290 work?
Gradually, not acutely. You will not notice anything in the first week or two. In trials, significant improvement over placebo appeared around week 2-4, with peak response at 6-12 weeks. Give it at least 4-6 weeks at 4 mg SubQ daily before judging — it works through tissue-level healing, not immediate analgesia.
What is the standard dose?
4 mg subcutaneously once daily — the dose used in Phase 2 trials for both sarcoidosis-SFN and diabetic neuropathy. Beginners often start at 2 mg daily for the first week. Higher doses have not shown superior efficacy, likely because the receptor is saturated at this level.
Is ARA-290 safe for long-term use?
Short-term safety (up to ~6 months in trials) has been excellent, with mild injection-site reactions as the main issue and no thrombotic, hypertensive, or polycythemia signals. Long-term data beyond 6-12 months are limited. Prudent long-term practice includes planned drug holidays, ongoing monitoring (CBC, blood pressure), and periodic re-evaluation of benefit.
Can ARA-290 affect tumor growth?
It is a theoretical concern. ARA-290 does not activate the classical EPO receptor most linked to tumor-survival concerns, and trials have not shown increased malignancy, but the IRR pathway itself involves anti-apoptotic signaling. Patients with active malignancy or cancer within the past 5 years should not use it without explicit oncology coordination.
Is ARA-290 legal and does it need a prescription?
ARA-290 is not FDA-approved, so there is no approved prescribing label. It can be purchased as a research chemical for laboratory use in most jurisdictions (not for human consumption). Legitimate access routes include clinical trial enrollment, physician-directed compounding pharmacy prescriptions in some jurisdictions, or research peptide suppliers with verified COAs.
How does it compare to BPC-157 and TB-500?
They work through different, complementary mechanisms. BPC-157 promotes epithelial/GI healing and angiogenesis, TB-500 supports cell migration and matrix remodeling, and ARA-290 reduces inflammation and protects cells via the innate repair receptor — with its strongest evidence in neuropathic pain. They are commonly stacked for complex injury recovery, though combined use is mechanism-based rather than trial-proven.
